NCT02694523 - BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

684

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Psoriasis

Interventions

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo risankizumab administered by subcutaneous (SC) injection

BIOLOGICAL

placebo for adalimumab

Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection